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Rapid Disease Progression in Human Immunodeficiency Virus Type 1-Infected 
Individuals with Adverse Reactions to Trimethoprim-Sulfamethoxazole 
Prophylaxis
Jan Veenstra, Paul J. Veugelers, Ireneus P. M. Keet, 
Andre J. A. M. van der Ven, Frank Miedema, 
Joep M. A. Lange, and Roel A. Coutinho
We studied the relation between the occurrence of adverse reactions to trimethoprim-sulfamethox- 
azole (TMP-SMZ) prophylaxis and the subsequent course of human immunodeficiency virus (HIV) 
infection in a cohort of homosexual men. Adverse reactions to TMP-SMZ were associated with a 
more rapid progression to AIDS (P <  .001) and death (P <  .001) and with a more rapid decline 
in CD4 ' cell counts (P = .001). The median time to progression to AIDS was 14.9 months in 
subjects with adverse reactions to TMP-SMZ and 32.5 months in those without adverse reactions. 
After exclusion of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis from the case definition 
of AIDS, the differences in the rate of progression to AIDS between subjects with and without 
adverse reactions to TMP-SMZ were still highly significant (P =  .004). A low CD4+ cell count at 
baseline and the use of antiretroviral agents before the start of prophylaxis were predictors of 
adverse reactions to TMP-SMZ but did not account for the difference in progression to AIDS 
between subjects with and without adverse reactions to TMP-SMZ. In a univariate analysis, the 
relative hazard of adverse reactions to TMP-SMZ for progression to AIDS was 2.54 (95 % confidence 
interval [Cl], 1.50-4.28); in a multivariate analysis, it was 2.21 (95% Cl, 1.29-3.81). The relative 
hazards of adverse reactions to TMP-SMZ for progression to AIDS with the exclusion of PCP and 
toxoplasmosis, CD4+ cell counts of <50/mm3, and death were 2.16 (95% Cl, 1.25-3.72), 2.37 (95% 
Cl, 1.36-4.12), and 3.21 (95% Cl, 1.80-5.72), respectively. It is unclear whether adverse reactions 
to TMP-SMZ induce or merely predict progression of HIV disease.
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Trimethoprim-sulfamethoxazole (TMP-SMZ) is highly ef- aerosolized pentamidine and oral dapsone, are less effective as
fective as treatment and prophylaxis for initial and recurrent prophylaxis for P. carinii infections and toxoplasmosis [7, 8].
episodes of Pneumocystis carinii pneumonia (PCP) [1-3]. In 
addition to its efficacy in preventing PCP, TMP-SMZ also 
protects against toxoplasmosis and several bacterial infections 
[3-5]. Although TMP-SMZ is the preferred drug for prophy­
laxis for PCP, about one-quarter of HIV type 1 (HIV-1 ) -  
infected individuals experience adverse reactions that occur 
mostly within the first month of treatment [61. The alternatives,
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We studied the relation between the occurrence of adverse 
reactions to TMP-SMZ prophylaxis and the subsequent course 
of HI V infection in a cohort of homosexual men. We found a 
relatively large difference in survival from the start of PCP 
prophylaxis to death between HIV-1-infected patients without 
adverse reactions to TMP-SMZ and those with adverse reac­
tions to TMP-SMZ. Patients with adverse reactions to 
TMP-SMZ subsequently had a more rapid progression of HIV 
infection that could only partly be explained by an increased 
incidence of PCP or toxoplasmosis.
Patients and Methods
Patient population. In 1984, a prospective study on HIV 
infection and AIDS in sexually active homosexual men was 
started (The Amsterdam Cohort Study) [9]. HIV-1-seropositive 
subjects were seen every 3 months; during the visits, a standard­
ized medical history was taken, a physical examination was 
performed, and blood samples were drawn. Included in our 
study were AIDS-free IilV -1-infected subjects who partici­
pated in the cohort study for at least 1 year before they started
CID 1997; 24 (May) TMP-SMZ and Progression of HIV Infection 937
receiving TMP-SMZ as primary prophylaxis for PCP. The cen- AIDS, CD4 ' cell counts of <50/mnv\ and death were evalu-
ated by using Kaplan-Meier survival methods and logrank sta-
ti sties.
Differences in progression to AIDS might reflect differences
soring date of our study was 31 August 1995.
PCP prophylaxis. Since February 1990, asymptomatic 
HIV-1-infected subjects were advised to start primary prophy­
laxis for PCP when they had two consecutive CD4+ cell counts in the efficacy of prophylaxis with TMP-SMZ vs. aerosolized 
of <200/mnr\ In February 1991, the criterion for starting pro- pentamidine. Therefore, the above-mentioned analysis was re- 
phylaxis was changed: asymptomatic HIV-1-seropositive sub- peated with (1) the exclusion of PCP and toxoplasmosis 
jects were advised to start PCP prophylaxis when they had one the case definition of AIDS and the use of a subsequent AIDS-
CD4+ cell count of < 2 00/mm3. defining condition instead and (2) the exclusion of PCP and
TMP-SMZ was prescribed as PCP prophylaxis for all pa- toxoplasmosis as primary AIDS-defining events entii
tients except three with a history o f adverse reactions to the degree of immunodeficiency, the criterion for
TMP-SMZ and seven who participated in an early study of the phylaxis, the dose of TMP-SMZ, and concomitant antiretroviral
efficacy of zidovudine, in which only aerosolized pentamidine therapy might be associated with the risk for AIDS and
was allowed as PCP prophylaxis [10]; these 10 subjects were we evaluated the effect of adverse reactions to TMP-SMZ by
not included in our study. The initial dose of TMP-SMZ was 
960 mg once daily. In August 1991, the TMP-SMZ dose was 
changed to 480 mg, following a randomized trial that showed 
that the lower dose had an equal clinical efficacy but fewer 
side effects [2]. Prophylaxis for all subjects who had to stop 
taking TMP-SMZ because of adverse reactions was changed 
to aerosolized pentamidine (300 mg once every 4 weeks).
Comedication. The administration of drugs that might in-
means of Cox regression 
adjustments for these factors.
Results
Between February 1990 and September 1995, 112 AIDS- 
free HIV-1-infected men (of whom 84 were HIV-seropositive 
at entry in the cohort and 28 seroconverted to HIV during
fluence the metabolism of TMP-SMZ and those that were used follow-up) started receiving TMP-SMZ as primary prophylaxis
between the start of TMP-SMZ prophylaxis and the occurrence 
of adverse events was noted.
Definitions. Adverse reactions to TMP-SMZ were defined 
as follows: fever (temperature o f >38.5°C), skin rash, 
and/or gastrointestinal symptoms occurring within 2 months
for PCP. All patients except one were Caucasian. TMP-SMZ 
prophylaxis was stopped permanently for 33 (29%) of the men 
because of adverse reactions. Fever and/or skin rash occurred 
in 31 patients (fever and skin rash,'21; fever only, 5; skin rash 
only, 5); eight of these 31 patients also had gastrointestinal
after starting prophylaxis; an event that resolved when symptoms. Two of 33 subjects stopped TMP-SMZ prophylaxis 
TMP-SMZ treatment was stopped; and the permanent discon- because of gastrointestinal symptoms without fever or skin
tinuation of TMP-SMZ treatment. AIDS was defined according 
to the 1987 revised case definition o f the Centers for Disease Adverse reactions to -SMZ occurred at a later stane of
Control and Prevention [11].
Laboratory methods. Peripheral blood mononuclear cells 
were isolated from heparinized venous blood by using density 
gradient centrifugation in Ficoll-Hypaque solution (Phar­
macia, Piscataway, NJ). Lymphocyte immunophenotyping 
was determined by flow cytometry. T cell reactivity was mea­
sured by stimulating cells with CD3 monoclonal antibody 
(Central Laboratory of the Red Cross Blood Transfusion Ser­
vice, Amsterdam) and is expressed in counts per minute (nor­
mal T cell reactivity based on the 95% confidence limit,
HIV infection in the group receiving 480 mg than in the group 
receiving 960 mg (median of 19 days [range, 7 -60 vs.
median of 15 days [range, 5 -46], respectively). Only one of
of TMP-SMZ prophylaxis; none of the patients were receiving 
fluconazole, rifampin, or eimetidine therapy concomitantly.
occurrence or absence of adverse reactions to 
TMP-SMZ cannot be associated with the influence of these
P-450zs on
TMP-SMZ. It is
5*1,100 counts per minute) [12]. To detect the presence of to drugs other than TMP-SMZ, since none of 
syncytium-inducing (SI) HIV-1 variants, which are associ- started receiving therapy with other drugs between the start of
ated with a more rapid decline in CD4+ cell count and a more 
rapid disease progression [13], peripheral blood mononuclear 
cells were cocultivated with MT-2 cells [14].
Statistical methods. The predictive potential of demo-
v*>.
\ ƒ *
Logistic regression was used to determine which variables
***** * 4\
graphic data and laboratory markers for the occurrence of ad- (table 1 ). A relatively low CD4
verse reactions to TMP-SMZ was evaluated by using logistic cell counts of <200/nim^ before the start of TMP-SMZ prophy- 
regression with likelihood ratio tests (P <  .05) in backward laxis were found to be predictors for the development of ad-
and forward selection procedures. Differences in disease pro­
gression between men with and men without adverse reactions 
to TMP-SMZ from the start of TMP-SMZ prophylaxis to
verse reac 2 as a i in I in
start of TMP-SMZ is, T
-
\ tv*e
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Table 1. Baseline characteristics o f HIV-infected patients with and without adverse reactions to TMP- 
SMZ and their predictive value for the occurrence o f  adverse reactions.
Patients without Patients with
adverse reactions adverse reactions
Characteristic (n = 79) (n -  33) OR (95% Cl)
Mean age (y) 39.7 39.1
Median CD41 cell count (/mm3) 160 140 0.33 (0.13-0.83)
Median T cell reactivity (cpm) 570 340 0.96 (0.71-1.29)
Median annual decline in CD4+ cell
count (/mm-’) 82 105 1.29 (0.72-2.27)
No, (%) with repeated CD41 cell counts
of <2()()/mirr' 39 (49) 25 (76) 3.20 (1.27-8.11)
No. (%) with SI virus phenotype 8 (10) 19 (58) 1.58 (0.67-3.69)
No. (%) receiving 960 mg of TMP-SMZ 42 (53 ) 24 (73) 2.33 (0.92-5.08)
No. (%) receiving antiretroviral therapy 28 (35) 18 (55) 2.19 (0.94-5.08)
NOTE, epm = counts per minute; SI = syncytium-inducing; TMP-SMZ = trirnethoprim-sulfamethoxazole, ORs 
express a protective cfleet for adverse reactions to TMP-SMZ per elevations of 100/mm'1 in CD41 cell counts and 
elevations of 1,000 cpm in T cell reactivity. ORs express an increased risk for adverse reactions to TMP-SMZ per 
declines of 100/mm5 in CD4+ cell counts in the year before the start of TMP-SMZ prophylaxis, for repeated CD41 
cell counts of <200/mm\ for the presence of SI virus variants, for a high does of TMP-SMZ (960 mg), and for the 
use of antiretroviral agents before the start of TMP-SMZ prophylaxis.
A high dose of TMP-SMZ and the use of antiretroviral agents treated with aerosolized pentamidine and in another patient 
(zidovudine and, for a few patients, zidovudine combined with without adverse reactions to TMP
another nucleoside analogue) before the start of TMP-SMZ 
prophylaxis were associated with the occurrence of adverse 
reactions, but these associations were not statistically signifi­
cant. In a multivariate analysis, after correction for CD4+ cell 
counts, the odds ratio for the use of antiretroviral agents before
the start of prophylaxis increased to 2.72 (P .03).
AIDS developed in 26 (79%) of 33 patients with adverse 
reactions and in 37 (47%) of 79 patients without reactions to 
TMP-SMZ (table 2). PCP occurred in one patient who was
T able 2. The first AIDS-defining disease and the number of deaths 
in I-IIV-infected patients with and without adverse reactions to 
TMP-SMZ.
Variable
Patients without 
adverse reactions
Patients with 
adverse reactions
No. of patients 79 33
No. (%) of deaths 28 (35) 23 (70)
No. (%) of patients with
AIDS
K l i \  t t n f  U 1 m t \ 4 i i  w l  f t  «4
37 (47) 26 (79)
i 1 VJ ♦ Vt 1 1 ! J l i J  vl 1: w i t  IWVI LI Jl Ci v
AIDS-defining event
PCP 1 1
Toxoplasmosis of the brain 0 8
Kaposi’s sarcoma 6* 6
Candidal esophagitis 14* 6
Other 16 5
NOTE. PCP = Pneumocystis carinii pneumonia; TMP-SMZ = trimetho- 
prim-sulfamethoxazoie.
* Another AIDS-defining disease was diagnosed concurrently for one patient 
with Kaposi’s sarcoma (cryptosporidiosis) and one with candidal esophagitis 
(cryptococcal meningitis).
-SMZ who had not taken 
prophylaxis for several months. Toxoplasmosis of the brain 
occurred as the first AIDS-defining event in eight (24%) of 33 
patients with adverse reactions to TMP-SMZ but in none of 
the patients without adverse reactions (P <  .001).
The association of adverse reactions to TMP-SMZ with pro­
gression of HIV disease from the start of TMP-SMZ prophy­
laxis (baseline) was evaluated by means o f Kaplan-Meier sur­
vival analysis. Adverse reactions to TMP-SMZ were associated 
with faster progression to AIDS, death, and CD41 counts
of < 50/mm3 (figure 1). The median time from the start of 
prophylaxis to progression to AIDS was 14.9 months for sub­
jects with adverse reactions to TMP-SMZ and 32.5 months for 
patients without adverse reactions. The median time from the 
start of TMP-SMZ prophylaxis to death was 28.3 months in
subjects with adverse reactions and 51.9 
without adverse reactions.
s in patients
When PCP and toxoplasmosis were excluded from the case 
definition of AIDS and a subsequent AIDS-defining condition 
was used instead, the differences in the rate of progression to
AIDS were still highly significant (figure 1). In addition, when 
patients for whom PCP or toxoplasmosis was the AIDS-defin­
ing event were excluded from the analysis, the differences 
remained significant (P — .004). Thus, the difference in pro­
gression to AIDS in patients with and without adverse reactions 
to TMP-SMZ is not merely a reflection of the prophylactic 
effect of this therapy on toxoplasmosis.
Cox regression (proportional hazards analysis) was used to 
determine whether the differences in progression to AIDS 
between patients without reactions to
TMP-SMZ could be explained by differences at the start of
CID 1997; 24 TMP-SMZ and Progression of HIV Infection
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Figure 1, Kaplan-Meier survival curves for HIV-infected patients who did 
to prophylaxis with trimethoprim-sulfamethoxazole; the curves show the
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•s) and who did not in c’.v ) have adverse reactions
as in time to progression to AIDS (A), AIDS with the 
exclusion o f Pneumocystis carinii pneumonia and toxoplasmosis as AIDS-defining conditions (5), the first CD4 ' cell count of <  50/mm5 (C ), 
and death ( D ).
prophylaxis (table 3). The relative hazard of adverse reactions 
to TMP-SMZ for progression to AIDS was 2.54 (95% Cl, 
1.50-4.28). In a univariate analysis, a low CD 41 cell count at 
the start of TMP-SMZ prophylaxis, repeated CD4 ' 
o f <200/mm3 before the start of prophylaxis, and a low T cell 
reactivity were also significantly associated with progression 
to AIDS (table 3). Biological virus phenotype (S1/NS1), the 
dose of TMP-SMZ, and the use of antiretroviral agents before 
the start of prophylaxis were not statistically associated with
< 50/mm3 (RM, 2.37; 95% Cl, 1.36.4.12), and death (RH,
3.21; 95% CI. 1. *.*(■*03 5.72).
Discussion
reveals a between the occur
rence of adverse reactions to TMP-SMZ and the course of HIV
•se reactions to
a more rapid progression to AIDS and death and with a more
progression to AIDS. The relative hazard of adverse reactions rapid decline in CD4 counts. In agreement with
ings o f other investigators [3, 5, 15], we 
decrease in the incidence of
event, in patients treate 
the difference in the rate of
xi a sto TMP-SMZ was not substantially altered by controlling lor 
CD4 * cell counts, repeated CD4+ cell counts of < 200/mm3, 
and T cell reactivity at baseline (bivariate analysis; table 3).
Multivariate analysis demonstrated that adverse reactions to 
TMP-SMZ, a low CD4+ cell count at baseline, a low T cell 
reactivity, and the use of antiretroviral agents before the start solized pentamidine could not be explained by this 
of TMP-SMZ prophylaxis were independently associated with 
faster progression to AIDS (table 3). Similar associations with 
adverse reactions were found in an analysis of progression to
Í icant
to
patients treated with TMP-SMZ and patients treated with aero-
m pr acy.
A low CD4 CD4 counts of
< 200/m m \ T cell reactivity at baseline, and, in a
i f  #11*AIDS with the exclusion of PCP and toxoplasmosis (relative analysis, the use of antiretroviral 
hazard [RH], 2.16; 95% Cl, 1.25-3.72), C D 41 cell counts of prophylaxis were also statistically associated with a more rapid
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Table 3. Relative hazards for progression to AIDS in HIV-infected dependable predictors of adverse reactions to TMP-SMZ. The 
men with and without adverse reactions to TMP-SMZ. incidence of rashes due to TMP-SMZ in HIV-infected individu­
als with CD4+ cell counts of < 200/mm3 was higher than that 
in HIV-infected individuals with higher CD4+ cell counts in 
one study [16].
Similar results have been observed for HIV-1-infected indi­
viduals treated with amoxicillin/clavulanate [17]. However, in 
a study of HIV-1 -positive patients with advanced infection who 
received high dosages of TMP-SMZ (120 mg/[kg • d]) during 
treatment of PCP [18], it was found that adverse reactions 
occurred more often in patients with high CD8 ' or CD4+ cell 
counts and that adverse reactions could be predicted by a 
CD4+/CD8+ ratio of >0.10. The latter correlation was not 
observed by other investigators [19].
It is not clear whether the discrepancy in the relation between 
CD4+ cell count and adverse reactions to TMP-SMZ is ex­
plained by the different degree of immunodeficiency, the large 
difference in the dose of TMP-SMZ, or the presence of active 
PCP. An increase in the incidence of adverse reactions to 
TMP-SMZ in early stage HIV disease and a decrease in the 
incidence of these reactions in late stage HIV disease might 
explain this discrepancy.
Use of antiretroviral agents before the start of TMP-SMZ 
prophylaxis was a predictor of adverse reactions to TMP-SMZ 
and was also associated with a more rapid progression to AIDS 
and death. An interaction of zidovudine and TMP-SMZ or a 
difference in the degree of disease progression that is not re-
Analysis, factor
Relative hazard 
(95% Cl)
Univariate
Adverse reactions to TMP-SMZ 2.54 (1.50-4.28)
CD4+ cell count per 100/mm3 0.34 (0.18-0.64)
Repeated CD4'h cell counts of < 200/mm3 2,16 (1.19-3.90)
T cell reactivity per 1,000 cpm 0,54 (0.34-0.86)
SI virus phenotype 1,35 (0.81-2.26)
480-mg dose of TMP-SMZ 0.64 (0.33-1.21)
Antiretroviral therapy before TMP-SMZ
prophylaxis 1.66 (0.98-2.80)
Divariate
Adverse reactions to TMP-SMZ 2,29 (1.33-3,92)
CD4+ cell count per 100/mm3 0.40 (0.22-0,74)
Adverse reactions to TMP-SMZ 2.30 (1.35-3.91)
Repeated CD4h cell counts of <200/mm3 1.91 (1.05-3.47)
Adverse reactions to TMP-SMZ 2.60 (1.54-4.39)
T cell reactivity per 1,000 cpm 0.55 (0.35-0.86)
Multivariate
Adverse reactions to TMP-SMZ 2,21 (1.29-3.81)
CD4+ cell count per 100/mm3 0,41 (0.21-0.81)
T cell reactivity per 1,000 cpm 0.62 (0,40-0.94)
Antiretroviral therapy before TMP-SMZ
prophylaxis 1.97 (1.14-3.41)
NOTE. cpm = counts per minute; SI = syncytium-inducing; TMP-SMZ 
= trimethoprim-sulfamethoxazole. Relative hazards were determined for the 
presence of adverse reactions to TMP-SMZ per elevations of 100/mm3 in 
CD4+ cell counts and elevations of 1,000 cpm in T cell reactivity, for repeated 
CD4+ cell counts of <200/mm\ for the presence of SI virus variants, for a 
low dose of TMP-SMZ (480 mg), and for the use of antiretroviral agents 
before the start of TMP-SMZ prophylaxis.
fleeted in CD4 cell counts might explain the increased risk 
of adverse events. The transient effect of zidovudine on CD4+ 
cell counts and disease progression may have already ended 
in patients who used antiretroviral agents before (median time, 
22.7 months) the start of TMP-SMZ prophylaxis, which might 
explain their shortened survival [20].
It is not clear whether adverse reactions to TMP-SMZ merely 
indicate or also induce progression of HIV disease. A genetic 
predisposition for the occurrence of adverse reactions as well 
cell count at baseline, repeated CD4+ cell counts of as for the progression of HIV disease might explain the associa- 
<200/m m \ and the use of antiretroviral agents before the start tion. Adverse reactions to TMP-SMZ may be a marker for 
of PCP prophylaxis were associated with the occurrence of biological processes that affect the progression of HIV disease.
progression to AIDS and death but did not interfere with the 
association with adverse reactions. Furthermore, a low CD4+
adverse reactions to TMP-SMZ.
It is highly unlikely that differences in survival and in de-
Oxidative stress is a potent inducer of both viral activation and 
''fA damage in infected cells [21, 22] and might be a factor in
clines in CD41 cell counts between patients with and without the progression of HIV disease [23]. Increased levels of oxidized 
adverse reactions to TMP-SMZ might be due to a direct effect glutathione in CD41 lymphocytes of HIV-infected individuals
of TMP-SMZ or aerosolized pentamidine on the progression have recently been reported [24]; these increased levels indicate
of HIV-1 infection. In two prospective trials of increased oxidative stress. Oxidation also generates the unstable
TMP-SMZ vs. aerosolized pentamidine as prophylaxis for PCP hydroxylamine metabolite of sulfamethoxazole, and it has been
[3, 15], no significant differences in overall mortality were postulated that this intermediate plays a central role in the develop-
found, and no differences in declines in CD4+ cell counts 
were reported. The present study illustrates that differences in 
survival between treated and untreated individuals that are
ment of adverse reactions to TMP-SMZ [25].
An accelerated progression o f HIV disease could also have 
been induced by the occurrence of adverse reactions to
found in on-treatment analysis of drug efficacy trials may re- TMP-SMZ. The association of fever with skin rash and the
fleet a selection of patients rather than a treatment effect. lower incidence of adverse reactions to TMP-SMZ in patients
In the present study, a relatively low CD4+ cell count at treated with corticosteroids [18, 26] suggest that inflammatory 
baseline and repeated CD4+ cell counts of <200/mm3 were cytokines may be involved. Several cytokines can activate
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European-Australian Collaborative Group (Study 017). AIDS 1994; 8; 
313-21.
11. Centers for Disease Control. Revision of the case definition of acquired
immune deficiency syndrome. MMWR Mortal Morb Wkly Rep 1987; 
36(suppl):lS-15S.
12. Roos MTL, Miedema F, Root M, et al. T cell function in vitro is an
independent progression marker for AIDS in human immunodeficiency 
virus-infected asymptomatic subjects. J Infect Dis 1995;171:531-6.
13. Koot M, Keet IPM, Vos AHV, etal. Prognostic value of HIV-1 syncytium-
inducing phenotype for rate of CD4'1' cell depletion and progression to 
AIDS. Ann Intern Med 1993;118:681-8.
on PCP and toxoplasmosis. The degree of immunodeficiency 14, Koot M, Vos AI-I, Keet IPM, et al. HIV-1 biological phenotype in long­
term infected individuals evaluated with an MT-2 cocultivation assay.
HIV replication that might lead to an accelerated progression 
of HIV-1 disease [27], Alternatively, immunosuppression 
might be induced by the formation of sulfamethoxazole hy- 
droxylamine; this metabolite inhibits the activity of natural 
killer cells [28] and induces a profound suppression of T cell 
proliferation [29].
In conclusion, adverse reactions to TMP-SMZ were associ­
ated with a more rapid progression of HIV-1 infection that 
could not be explained by the preventive effect of TMP-SMZ
and the use of antiretroviral agents before the start of prophy­
laxis were predictors of adverse reactions to TMP-SMZ but 
did not account for the differences in survival. Whether adverse 
reactions to TMP-SMZ induce or merely indicate progression 
of HIV-1 infection is unclear.
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